Accueil / Communiqués / Cadent Therapeutics Appoints Jodie Morrison as Chief Executive Officer

Cadent Therapeutics Appoints Jodie Morrison as Chief Executive Officer

Thursday, February 14th 2019 at 11:00am UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Cadent Therapeutics, a company focused on the development of
breakthrough therapies to improve the lives of patients with movement
and neurological disorders, today announced that Jodie Morrison has been
appointed Chief Executive Officer and has also joined Cadent’s Board of
Directors. Ms. Morrison brings to Cadent more than 20 years of executive
leadership and therapeutics development experience in the
biopharmaceutical industry. Michael Curtis, Ph.D., who has served as the
Company’s President and CEO, will remain as President and Head of
Research and Development at Cadent.

“Jodie has a deep background in executive, operational, and clinical
development leadership, having successfully guided the growth and
development of emerging biopharmaceutical companies across multiple
therapeutic areas,” said Peter Barrett, Ph.D., Partner at Atlas Venture
and Chairman of the Board. “Jodie’s appointment comes at an important
period of growth for Cadent, fueled by a successful Series B financing,
progress in the clinic for our lead program in two progressive
neurological conditions, and the advancement of a second program toward
the clinic. We look forward to benefiting from her leadership as Cadent
continues to build value through its mission of improving the lives of
people with movement and cognitive disorders.”

“Cadent has taken an innovative approach to creating first-in-class
therapies to treat unmet needs in movement and cognitive disorders,”
said Ms. Morrison. “Backed by top tier investors and a license deal with
Novartis, a global leader in neuroscience, the Company is well
positioned to deliver meaningful impact for patients with essential
tremor, spinocerebellar ataxia and schizophrenia. I look forward to
working with the Cadent team as we deliver on the promise of our very
exciting and diverse pipeline.”

Ms. Morrison most recently served as interim Chief Executive Officer at
Keryx Biopharmaceuticals, Inc. Previously she served as President and
Chief Executive Officer of Tokai Pharmaceuticals, Inc. Prior to being
appointed President and Chief Executive Officer at Tokai, Ms. Morrison
held other senior positions with the company, including Chief Operating
Officer, Head of Clinical Affairs and Program Operations, and Vice
President of Clinical Affairs and Program Operations. Prior to joining
Tokai, Ms. Morrison held roles in clinical operations and medical
affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. Ms. Morrison
received a B.A. in neuroscience from Mount Holyoke College, her clinical
research certification from Boston University School of Medicine, and
her business training through the Greater Boston Executive Program at
the MIT Sloan School of Management. Ms. Morrison currently sits on the
Board of Directors for Akebia Therapeutics (AKBA) and Aileron
Therapeutics (ALRN).

About Cadent Therapeutics

Cadent Therapeutics is creating breakthrough therapies for the treatment
of movement disorders and cognitive impairment. The company combines
target specificity, patient selection, drug design and optimization, and
novel quantitative endpoints to create first-in-class molecules to treat
movement and cognitive disorders. Cadent Therapeutics is rapidly
advancing its pipeline of positive allosteric modulators to treat
spinocerebellar ataxia, essential tremor and schizophrenia. The company
has an exclusive license and collaboration agreement with Novartis to
develop a negative allosteric modulator, now in Phase 1 clinical studies
for the treatment of treatment resistant depression. Investors include
Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners,
Access Industries, Clal Biotechnology Industries, Novartis Institutes
for Biomedical Research and Slater Technology Fund. For more
information, please visit cadenttx.com.

Contacts

Investors:
Maeve Conneighton, maeve@argotpartners.com
212.600.1902

Media:
David
Rosen, david.rosen@argotpartners.com
212.600.1902

Source: Cadent Therapeutics


Voir aussi

Maverick Therapeutics to Unveil Pre-Clinical Data on Novel COBRATM Platform at American Association for Cancer Research 2019 Annual Meeting

Saturday, March 30th 2019 at 12:00pm UTC – Pre-clinical Data Characterize the Conditional and Potent …